Cd19 Positive clinical trials

Explore recruiting cd19 positive clinical trials.

Recruiting cd19 positive studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cd19 Positive trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

DK-CLIC-1901 CAR T-cells for treatment of patients with relapsed/refractory CD19 positive hematological malignancies (DAN-CART 1901)

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase I safety, dose finding and feasibility trial of MB-CART19.1 in patients with relapsed or refractory CD19 positive B cell malignancies

Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020

Netherlands, Czechia, Italy, Spain, Denmark, Austria +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)

Belgium, Denmark, Netherlands, Sweden, Spain, Romania +11 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Single-Arm, Open-Label, Multicenter, Phase 1b/2 Study Evaluating the Safety and Efficacy of AUTO1 (obecabtagene autoleucel [obe-cel]) in Pediatric Patients with CD19-positive Relapsed/Refractory (R/R) B cell Acute Lymphoblastic Leukemia (B ALL) or R/R Aggressive Mature B Cell Non–Hodgkin Lymphoma (B NHL)

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

An open label multicenter phase II study to investigate the efficacy, safety and tolerability of the Obe-cel in patients with minimal residual disease (MRD) of Philadelphia negative (Ph neg) B-precursor acute lymphoblastic leukaemia (B-ALL) - GMALL-OBECEL

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Cd19 Positive trials by city

Cd19 Positive in Toronto Cd19 Positive in Vancouver Cd19 Positive in Montreal Cd19 Positive in Calgary Cd19 Positive in Edmonton Cd19 Positive in Ottawa Cd19 Positive in Winnipeg Cd19 Positive in Quebec City Cd19 Positive in Hamilton Cd19 Positive in Kitchener Cd19 Positive in London Cd19 Positive in Halifax Cd19 Positive in New York Cd19 Positive in Los Angeles Cd19 Positive in Chicago Cd19 Positive in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease